Norwich, CT, United States of America

James John Mousseau

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of James John Mousseau

Introduction

James John Mousseau is a notable inventor based in Norwich, Connecticut. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific receptors in the body. With a total of three patents to his name, Mousseau's work has the potential to impact the treatment of various diseases.

Latest Patents

Mousseau's latest patents include innovative compounds known as N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides, which are useful as CCR6 inhibitors. These compounds are designed to inhibit the CC chemokine receptor 6 (CCR6), which plays a role in various diseases and conditions. The patents detail the pharmaceutical compositions containing these compounds and their applications in treating or preventing disorders that can be ameliorated by CCR6 inhibition.

Career Highlights

Throughout his career, Mousseau has worked with prominent organizations, including Pfizer Corporation and the Cystic Fibrosis Foundation. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of Mousseau's notable coworkers include Brian Stephen Gerstenberger and Andrew Christopher Flick. Their collaborative efforts have further advanced the research and development of innovative pharmaceutical solutions.

Conclusion

James John Mousseau's contributions to the field of pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…